67 research outputs found
Cost-benefit analysis of housing-related support services for homeless people: Cyrenians case study
Evaluation of Newcastleâs âcooperativeâ approach to the prevention and management of homelessness in light of changing Government policy
This was a follow up to a previous funded study and examined the manner in which services to prevent and tackle homelessness in Newcastle were developing in the face of substantial funding cuts
Participation with online recovery specific groups - findings from the UK Life in Recovery survey 2015
As the concept of recovery has expanded, and become embedded in drug and alcohol policy, so too has the proliferation of online recovery support. This article explores data from the UK Life in Recovery survey, focusing on online recovery methods categorized as online groups, websites, and smartphone applications. Although 301 people (39.30%) reported involvement with at least one online recovery method, chi-squared tests reveal significant associations between people in stable recovery (5 years or more) and the use of recovery applications (Cramerâs V = .114), as well as between people in full-time employment and the use of online recovery websites or recovery applications. Having dependent children was not associated with use of any online recovery method, yet gender was (Cramerâs V = .088). This study extends the relatively limited literature and knowledge base of online recovery methods. Although the evidence points to higher engagement of recovery websites and apps for people in stable recovery, encouraging online recovery methods for individuals in early recovery may support recovery efforts when the risk of returning to substance misuse and active using social networks remains high. Further research should investigate the mechanisms of recovery change, with a focus on gender differences
âHe did everything he possibly could for meâŠâ Medical malpractice claimantsâ experiences of legal services
Recommended from our members
Right Turn Veteran-Specific Recovery Service: 5 site evaluation pilot: Interim report
The Right Turn project works with the ex-service personnel community in recovery from substance misuse. This report presents the interim findings from a two-year evaluation on the impact on health and wellbeing outcomes on military veterans engaging in this innovative peer-focussed recovery service. The evaluation is designed around a structured quantitative data collection process using an established repeat measure design and utilises qualitative methodologies to explore both the life experiences of this veteran cohort and to take account of their own perceptions of the model of services they feel they require. This report suggests that the military veteran community experience distinct barriers to accessing main stream health and wellbeing services. Alongside comorbidity issues, management of chronic physical conditions and social isolation, this report demonstrates that this cohort's own previous military conditioning forms a further barrier to accessing support services. This report contains recommendations to inform generic support staff when encountering veterans within health and wellbeing settings
Recovery identity and wellbeing: is it better to be 'recovered' or 'in recovery'?
While there has been debate about the meaning of recovery, there has been little discussion about how people characterise their own recovery experience, in particular whether people describe themselves as 'recovered' (as with a therapeutic community (TC) philosophy) or as 'in recovery' (typically those engaged in 12-step). The paper assesses differences in wellbeing as a function of recovery self-ascriptions, based on the UK Life in Recovery survey. Those who described themselves as 'recovered' or 'ex-addicts' reported better psychological health and lower identification with addicts and recovery, and showed stronger recovery functioning. There are clearly multiple pathways to recovery, and philosophy may impact on both trajectory of recovery and the social identity mechanisms underpinning change
Immunogenicity of the RTS,S/AS01 Malaria Vaccine and\ud Implications for Duration of Vaccine Efficacy: Secondary\ud Analysis of Data from a Phase 3 Randomised Controlled Trial
The RTS,S/AS01 malaria vaccine targets the circumsporozoite protein, inducing antibodies associated with the prevention of Plasmodium falciparum infection. We assessed the association between anti-circumsporozoite antibody titres and the magnitude and duration of vaccine effi cacy using data from a phase 3 trial done between 2009 and 2014. Using data from 8922 African children aged 5 1317 months and 6537 African infants aged 6 1312 weeks at first vaccination, we analysed the determinants of immunogenicity after RTS,S/AS01 vaccination with or without a booster dose. We assessed the association between the incidence of clinical malaria and anti-circumsporozoite antibody titres using a model of anti-circumsporozoite antibody dynamics and the natural acquisition of protective immunity over time. RTS,S/AS01-induced anti-circumsporozoite antibody titres were greater in children aged 5 1317 months than in those aged 6 1312 weeks. Pre-vaccination anti-circumsporozoite titres were associated with lower immunogenicity in children aged 6 1312 weeks and higher immunogenicity in those aged 5 1317 months. The immunogenicity of the booster dose was strongly associated with immunogenicity after primary vaccination. Anti-circumsporozoite titres wane according to a biphasic exponential distribution. In participants aged 5 1317 months, the half-life of the shortlived component of the antibody response was 45 days (95% credible interval 42 1348) and that of the long-lived component was 591 days (557 13632). After primary vaccination 12% (11 1313) of the response was estimated to be longlived, rising to 30% (28 1332%) after a booster dose. An anti-circumsporozoite antibody titre of 121 EU/mL (98 13153) was estimated to prevent 50% of infections. Waning anti-circumsporozoite antibody titres predict the duration of effi cacy against clinical malaria across diff erent age categories and transmission intensities, and effi cacy wanes more rapidly at higher transmission intensity Anti-circumsporozoite antibody titres are a surrogate of protection for the magnitude and duration of RTS,S/AS01 effi cacy, with or without a booster dose, providing a valuable surrogate of eff ectiveness for new RTS,S formulations in the age groups considered
Immunogenicity of the RTS,S/AS01 malaria vaccine and implications for duration of vaccine efficacy:Secondary analysis of data from a phase 3 randomised controlled trial
BACKGROUND: The RTS,S/AS01 malaria vaccine targets the circumsporozoite protein, inducing antibodies associated with the prevention of Plasmodium falciparum infection. We assessed the association between anti-circumsporozoite antibody titres and the magnitude and duration of vaccine efficacy using data from a phase 3 trial done between 2009 and 2014. METHODS: Using data from 8922 African children aged 5-17 months and 6537 African infants aged 6-12 weeks at first vaccination, we analysed the determinants of immunogenicity after RTS,S/AS01 vaccination with or without a booster dose. We assessed the association between the incidence of clinical malaria and anti-circumsporozoite antibody titres using a model of anti-circumsporozoite antibody dynamics and the natural acquisition of protective immunity over time. FINDINGS: RTS,S/AS01-induced anti-circumsporozoite antibody titres were greater in children aged 5-17 months than in those aged 6-12 weeks. Pre-vaccination anti-circumsporozoite titres were associated with lower immunogenicity in children aged 6-12 weeks and higher immunogenicity in those aged 5-17 months. The immunogenicity of the booster dose was strongly associated with immunogenicity after primary vaccination. Anti-circumsporozoite titres wane according to a biphasic exponential distribution. In participants aged 5-17 months, the half-life of the short-lived component of the antibody response was 45 days (95% credible interval 42-48) and that of the long-lived component was 591 days (557-632). After primary vaccination 12% (11-13) of the response was estimated to be long-lived, rising to 30% (28-32%) after a booster dose. An anti-circumsporozoite antibody titre of 121 EU/mL (98-153) was estimated to prevent 50% of infections. Waning anti-circumsporozoite antibody titres predict the duration of efficacy against clinical malaria across different age categories and transmission intensities, and efficacy wanes more rapidly at higher transmission intensity. INTERPRETATION: Anti-circumsporozoite antibody titres are a surrogate of protection for the magnitude and duration of RTS,S/AS01 efficacy, with or without a booster dose, providing a valuable surrogate of effectiveness for new RTS,S formulations in the age groups considered. FUNDING: UK Medical Research Council
Recommended from our members
Thiopurine monotherapy is effective in ulcerative colitis but significantly less so in Crohnâs disease: long-term outcomes for 11 928 patients in the UK inflammatory bowel disease bioresource
Objective: Thiopurines are widely used as maintenance therapy in inflammatory bowel disease (IBD) but the evidence base for their use is sparse and their role increasingly questioned. Using the largest series reported to date, we assessed the long-term effectiveness of thiopurines in ulcerative colitis (UC) and Crohnâs disease (CD), including their impact on need for surgery. Design: Outcomes were assessed in 11 928 patients (4968 UC, 6960 CD) in the UK IBD BioResource initiated on thiopurine monotherapy with the intention of maintaining medically induced remission. Effectiveness was assessed retrospectively using patient-level data and a definition that required avoidance of escalation to biological therapy or surgery while on thiopurines. Analyses included overall effectiveness, time-to-event analysis for treatment escalation and comparison of surgery rates in patients tolerant or intolerant of thiopurines. Results: Using 68 132 patient-years of exposure, thiopurine monotherapy appeared effective for the duration of treatment in 2617/4968 (52.7%) patients with UC compared with 2378/6960 (34.2%) patients with CD (p<0.0001). This difference was corroborated in a multivariable analysis: after adjusting for variables including treatment era, thiopurine monotherapy was less effective in CD than UC (OR 0.47, 95% CI 0.43 to 0.51, p<0.0001). Thiopurine intolerance was associated with increased risk of surgery in UC (HR 2.44, p<0.0001); with a more modest impact on need for surgery in CD (HR=1.23, p=0.0015). Conclusion: Thiopurine monotherapy is an effective long-term treatment for UC but significantly less effective in CD
Act now against new NHS competition regulations: an open letter to the BMA and the Academy of Medical Royal Colleges calls on them to make a joint public statement of opposition to the amended section 75 regulations.
- âŠ